This study evaluates the effectiveness of photobiomodulation (PBM) in conjunction with mineral trioxide aggregate (MTA) pulpotomy for treating irreversible pulpitis in immature first permanent molars. PBM, also known as low-level laser therapy (LLLT), is used to enhance healing, reduce inflammation, and manage pain in young teeth. The randomized clinical trial involves 72 children aged 6-9 years, divided into two groups: one receiving MTA pulpotomy alone and the other receiving MTA pulpotomy with PBM. Clinical and radiographic outcomes will be assessed at intervals over 15 months. This research aims to determine the combined therapy's efficacy in improving pulp healing and reducing post-operative discomfort compared to MTA alone.
Children aged 6 to 9 years.
Non-contributory medical history (healthy otherwise).
Deep caries extending to ≥2/3 of dentin.
Positive response to cold testing.
Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp).
Presence of systemic or medical conditions that may contraindicate participation.
Teeth with unrestorable structure.
Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.